Hemophilia A and B are X-linked bleeding disorders characterized by partial or complete absence of clotting factors VIII and IX (FVIII and FIX, respectively). FVIII and FIX are critical coagulation ...

Patients with factor IX deficiency may be treated with a factor IX complex to manage an acute hemorrhage. Factor IX complexes contain 1 unit of factor IX per milligram of protein, with variable ...

The MarketWatch News Department was not involved in the creation of this content. -- Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and ...

Marstacimab significantly reduced ABR by 93% vs on-demand treatment over 12 months. Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with ...

HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis and on-demand treatment in eligible patients with hemophilia A or B ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved marstacimab-hncq for treatment of certain individuals with hemophilia. The indication applies ...

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...

A regulatory decision is expected in the second quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

THE question whether the circulating anticoagulants are antibodies is still unsettled. An attempt was made to examine the Christmas factor inhibitor (factor IX inhibitor, or P.T.C. [plasma ...

Antonarakis, S.E., Waber, P.G., Kittur, S.D., Patel, B.S., Kazazian, H.H., Jr., Mellis, M.A., Counts, R.B., Stamatoyannopoulos, G., Bowie, E.J.W., Fass, D.N., Pittman ...